Research-use-only status: what it means legally and practically — a second dataset posts 31–60

Research-use-only status has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.

Adding the measurement that post #45 says would settle it.

The documentation on Research-use-only status is better than this thread and I say that as someone who has posted in the thread.

Clear enough that I do not think I have a follow-up, which is unusual.

A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.

That much is documented. The rest is how I have interpreted it.

Answering the question post #45 raises rather than the one it answers.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Where I would look next, rather than where I would stop.

The arithmetic in post #49 is right; the assumption feeding it is the part to check.

The bit of Research-use-only status that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.

Research-use-only status sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.

Nothing to add, except that this is the answer I would give if asked.

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.

Happy to expand any of that if it is the useful part.

Where I part company with post #50, and it is a narrow parting.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Scoping that to what I have actually seen rather than what I have read.

Narrowing post #53, because the general version has more than one answer.

What I would tell a new member reading about Research-use-only status for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.

Research-use-only status would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.

Colour in a lyophilised cake is worth noting for the less common compounds specifically, because some of them are genuinely not white and a member expecting white will report a problem that is not one.

The strongest argument against my own position on Research-use-only status, stated as well as I can state it, since nobody else has yet.

Post #56 answers the question as asked. The question underneath it is different.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

The short answer was in the first line; everything after is the working.

I read post #58 twice before replying, because I had assumed the opposite.

Research-use-only status looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.